Author

Phil Jeffrey

Bicycle Therapeutics (United Kingdom)ORCID 0000-0003-4131-7218Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

Michael J. SkynneriD· 2 shared Adam KirbyiD· 1 shared Andrew OweniD· 1 shared Benedikt Mathias KessleriD· 1 shared Brian McGuinnessiD· 1 shared Eduardo Gallardo ToledoiD· 1 shared Edyta KijakiD· 1 shared Eleanor G. BentleyiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Michael J. SkynnerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 14, 2026

Spatial Tumour Tissue Distribution Dynamics of a Bicycle Peptide-MMAE Toxin Conjugate Profiled by Targeted Mass Spectrometry

Maria-Konstantina Ioannidi, Simon Davis, Tianen He…·Benedikt Mathias Kessler

This paper develops a spatial pharmacology workflow using LCM-LC-PRM to profile MMAE distribution in tumour and healthy tissues, revealing heterogeneous and time-dependent accumulation patterns.

DOI 10.64898/2026.10.13.758755

mouseproteomics

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintOct 3, 2025

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings

Maximilian A. J. Harman, Katherine U. Gaynor, Guido Papa…·Michael J. Skynner

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

DOI 10.1101/2025.10.03.680220

mouseexperimental assay

𝕏 PostBluesky